Olema Oncology (OLMA) Stifel 2026 Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Stifel 2026 Healthcare Conference 2026 summary
11 Nov, 2026OPERA clinical programs
OPERA-01, a 2L/3L monotherapy study, is expected to read out in Q1; the key test is whether phase II results replicate in phase III. Phase II median PFS was 7.3 months in ESR1-mutant and 5.5 months in wild-type patients.
Palazestrant’s proposed differentiators include a 14-day half-life, higher exposure and complete ER antagonism; OPERA-01 separately analyzes ESR1-mutant and wild-type populations.
OPERA-02, a first-line study with KISQALI, is enrolling robustly. Enrollment excludes endocrine-resistant patients with less than 6 months’ response to prior endocrine therapy in advanced disease.
OPERA-02 enrollment may be expanded after review of SERENA-4 control-arm data at San Antonio in early December; added enrollment would modestly extend timing, while readout depends on event rate.
Combination data and pipeline
San Antonio presentations will include mature post-CDK4/6 everolimus-combination data with Kaplan-Meier PFS, tolerability and ESR1-mutant/wild-type analyses.
Atirmociclib combination enrollment is complete; initial tolerability and response-rate data will be presented in a mixed frontline/post-CDK4/6 population, without mature durability data.
The KAT6 inhibitor poster will update monotherapy and show initial breast-cancer fulvestrant-combination tolerability across multiple dose levels; dose selection remains ongoing.
Palazestrant plus KAT6 data are targeted for mid-2027; prostate-cancer enrollment with NUBEQA is expected to start in the near future, with data earliest by late 2027.
Commercial strategy and financing
Success in both OPERA-01 populations could support an oral endocrine option across a broader market; management cited a ~$5B opportunity, including $3B with no competition, versus ~$2B for ESR1-mutant disease.
U.S. launch preparations are underway, with a potential launch around mid-2028 contingent on a positive, fileable OPERA-01 readout; plans include U.S. and ex-U.S. filings and seeking collaborators for launch and ex-U.S. markets.
Cash was $414M at Q3 end, expected to support the launch window conditional on OPERA-01; management cited a favorable cash position and potential non-equity capital options.
Latest events from Olema Oncology
- OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025 - Phase III breast cancer data expected in fall; KAT6 combos and strong cash position support growth.OLMA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Promising clinical progress and strategic trial updates position the pipeline for significant impact.OLMA
Jefferies Global Healthcare Conference 2026